Tenosynovitis

Summary

Tenosynovitis (MONDO:0004855) is a disease with 12 GWAS associations across 17 studies and 9 clinical trials. Top therapeutic interventions include ketorolac. A subtype of tendinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 12
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tenosynovitis
Mondo ID	MONDO:0004855
EFO	EFO:1001435
MeSH	D013717
DOID	DOID:970
ICD-11	163006370
SNOMED CT	67801009
UMLS	C0039520
MedGen	52670
Is cancer (heuristic)	no

Also known as: tendon sheath inflammation · Tenosynovitides

Data availability: 12 GWAS associations (17 studies).

Disease family

This is a subtype of tendinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › myopathy › myositis disease › tendinitis › tenosynovitis

Related subtypes (5): patellar tendinitis, tibialis tendinitis, Achilles bursitis, calcific tendinitis, paratenonitis

Subtypes (2): bicipital tenosynovitis, tenosynovitis of foot and ankle

Genetics & variants

GWAS landscape

12 GWAS associations across 17 studies. Top hits map to 6 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr16:69867835	3e-24		A	0.1
rs3790086	9e-22	WWP2	C	0.08
rs12694411	2e-18	TESHL	T	0.09
chr2:218146354	1e-17		T	0.12
chr7:46034024	3e-17		G	0.09
rs11076004	9e-13	FTO	G	0.07
rs2965069	3e-12	IGFBP3 - FTLP15	C	0.07
rs989437	6e-12	CREB5	A	0.06
rs7220854	1e-11	RNU7-155P - MYL6P5	T	0.07
chr17:69315666	2e-11		C	0.07
rs198462	2e-09	MYRF-AS1, MYRF	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476242	Verma A	2024	23,077	408,046	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080520	Backman JD	2021	8,632	371,813	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084506	Backman JD	2021	8,632	371,813	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90478948	Verma A	2024	6,832	109,011	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480517	Verma A	2024	6,832	109,011	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90080524	Backman JD	2021	5,503	375,456	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084510	Backman JD	2021	5,503	375,456	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90651333	Liu TY	2025	3,960	210,582	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90478947	Verma A	2024	3,748	53,173	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90044562	Jiang L	2021	3,692	452,656	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	11

MAF distribution

Bucket	Variants
common (>=0.05)	11
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	6
unknown	4
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr16:69867835				0.445			3e-24	Tier 4: intronic/intergenic
rs3790086	16	69853804	C>A,G,T	0.442	intron_variant	WWP2	9e-22	Tier 4: intronic/intergenic
rs12694411	2	217281820	T>A,C,G	0.385	intron_variant	TESHL	2e-18	Tier 4: intronic/intergenic
chr2:218146354				0.151			1e-17	Tier 4: intronic/intergenic
chr7:46034024				0.34			3e-17	Tier 4: intronic/intergenic
rs11076004	16	53880018	G>A,C,T	0.369	intron_variant	FTO	9e-13	Tier 4: intronic/intergenic
rs2965069	7	45978547	C>T	0.338	intron_variant	IGFBP3 - FTLP15	3e-12	Tier 4: intronic/intergenic
rs989437	7	28790881	A>G	0.398	intron_variant	CREB5	6e-12	Tier 4: intronic/intergenic
rs7220854	17	71311858	T>A,C	0.333	intergenic_variant	RNU7-155P - MYL6P5	1e-11	Tier 4: intronic/intergenic
chr17:69315666				0.37			2e-11	Tier 4: intronic/intergenic
rs198462	11	61756647	G>A,C,T	0.05	intron_variant	MYRF-AS1, MYRF	2e-09	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

7 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cortisone Acetate	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Hydrocortisone	Approved (phase 4)
Methylprednisolone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)
Triamcinolone Acetonide	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE4	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03704584	PHASE4	TERMINATED	Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone
NCT03792945	PHASE4	COMPLETED	Comparison of the Efficacy of Corticosteroid Injection and ESWT in Patients With CTS
NCT02266433	PHASE3	TERMINATED	Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
NCT06477965	Not specified	RECRUITING	Embo Registry; National Registry for Artery Embolization
NCT07553910	Not specified	NOT_YET_RECRUITING	Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis
NCT01424995	Not specified	COMPLETED	The Natural History of Congenital Trigger Thumbs
NCT02320929	Not specified	COMPLETED	The Treatment of Purulent Flexor Tenosynovitis
NCT03914235	Not specified	COMPLETED	Anesthesia Tumescent for Surgical Management of Tenosynovitis.
NCT06918158	Not specified	COMPLETED	Mobilization With Movement Versus Joint-Specific Manipulation in De Quervain’s Tenosynovitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
KETOROLAC	4	1